Zusammenfassung
Hodentumoren stellen die häufigste maligne Erkrankung bei jungen Männern zwischen dem 15. und 35. Lebensjahr dar. Die österreichische Krebsstatistik weist für das Jahr 1984 insgesamt 101 Hodentumoren in dieser Altersgruppe aus [1], das heißt, daß bei jedem 3. jungen Mann mit einer malignen Erkrankung ein Hodentumor diagnostiziert wird (Tabelle 1).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Krebskrankenstatistik 1984 (1986) Statistische Nachrichten 41: 172
Henderson BE, Ross RK, Pike MC, et al (1983) Epidemiology of testis cancer. In: Skinner DG (ed) Urological cancer. Crune and Stratton, New York, p 237
Waterhouse J, Muir C, Shanmugaratnam K, et al (eds) (1982) Cancer incidence in five continents, vol IV. International Agency for Research on Cancer, Lyon
Waterhouse J, Muir C, Correa P, et al (eds) (1976) Cancer incidence in five continents, vol VIII. International Agency for Research on Cancer, Lyon
Schottenfeld D, Warshauer ME (1982) Testis. In: Schottenfeld D, Fraumeni JS (eds) Cancer epidemiology and prevention. Saunders, Philadelphia, p 947
Depue RH (1984) Maternal and gestational factors affecting the risk of cryptorchidism and inguinal hernia. Int J Epidemiol 13: 311
Lin RS, Kessler I (1979) Epidemiologic findings in testicular cancer. Am J Epidemiol 110: 357
Loughlin JE, Robboy SJ, Morrison AS (1980) Risk factors for cancer of the testis. N Engl J Med 303: 112
Milham S (1976) Neoplasia in the wood and pulp industry. Ann NY Acad Sci 271: 294
Rhomberg W, Schmoll HJ (1978) High incidence of metal workers among patients with testicular cancer. In: Niebergs HE (ed) Prevention and detection of cancer, part I: prevention. Etiology prevention methods, volt. Marcel Dekker, New York, p 1737
Mills PK, Newell GR, Johnson DE (1984) Testicular cancer associated with employment in agriculture and oil and natural gas extraction. Lancet i: 207
Coldman AJ, Elwood JM, Gallagher RP (1982) Sports activities and risk of testicular cancer. Br J Cancer 46: 749
Jones WG, Appleyard I (1985) Delay in diagnosing testicular tumours. Br Med J 290: 1550
Forsberg L, Olsson AM (1983) Examination of the pathological scrotum with dynamic and static ultrasound. Br J Radio! 56: 921
Appleyard I (1986) Presentation of testicular tumours. In: Jones WG, Milford Ward A, Anderson CK (eds) Germ cell tumours II. Advances in the biosciences, vol 55. Pergamon Press, Oxford New York Toronto Sydney Frankfurt/M. p 295
Mostofi FK (1973) Testicular tumours: epidemiologic, etiologic and pathologic features. Cancer 32: 1186
Friedman NB, Moore RA (1946) Tumours of the testis: a report on 922 cases. Military Surgeon 99: 573
Dixon FJ, Moore RA (1952) Tumours of the male sex organs, fasc 31 b and 32. In: Atlas of tumour pathology. Armed Forces Institute of Pathology, Washington
Mostofi FK, Price EB (1973) Tumours of the male genital system, fasc 8. In: Atlas of tumour pathology (second series). Armed Forces Institute of Pathology, Washington
Mostofi FK, Sobin LH (1977) International histological typing of testes tumours, No 16. WHO, Geneva
Collins DH, Pugh RCB (1964) The pathology of testicular tumours. Livingstone, Edinburgh
Pugh RCB (1976) Combined tumours. In: Pugh RCB (ed) Pathology of the testis. Blackwell, Oxford, p 245
Kuzmits R, Schernthaner G, Krisch K (1987) Serum neuronspecific enolase: a marker for response to therapy in seminoma. Cancer 60: 1017
Kuzmits R, Aiginger P, Schwarz HP, et al (1983) HCG and Alpha-1-Fetoprotein bei Hodentumoren. Aktuelles aus Diagnostik and Therapie 81: 45
Kühböck J, Aiginger P, Kuzmits R, et al (1987) Prognostic value of tumour marker determinations in testicular cancer patients. Cancer Detect Prey 10: 389
Peckham MJ (1981) Investigation and staging: general aspects and staging classification. In: Peckham MJ (ed) The management of testicular tumours. Edward Arnold, London, p 89
Pschyrembel W (1982) Klinisches Wörterbuch, 254. Aufl. de Gruyter, Berlin New York, S 1232
Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: results of a multicentre study. Report from the Medical Research Council Working Party on Testicular Tumours (1985). Lancet is 8
Seeber S, Higi M, Niederle N, et al (1981) Individualisierte Intervallverkürzung bei der chemotherapeutischen Induktionsbehandlung solider Tumoren. Deutsch Med Wochenschr 106: 1741
Tapia FJ, Polak JM, Barbosa AJA, et al (1981) Neuron-specific enolase is produced by neuroendocrine tumours. Lancet is 808
Cooper EH, Splinter TAW, Brown DA, et al (1985) Evaluation of a radioimmunoassay for neuron-specific enolase in small cell lung cancer. Br J Cancer 52: 333
Aiginger P (1983) Prognostische Faktoren. In: Aiginger P (Hrsg) Neue Aspekte in der Klinik and Fortschritte in der Chemotherapie der malignen Hodentumoren. Facultas, Wien, S 49
Thomas GM, Rider WD, Dembo At et al (1982) Seminoma of the testis: results of treatment and patterns of failure after radiation therapy. Int J Rad Oncol Biol Phys 8: 165
Thomas GM, Herman JG (1984) The role of radiation in the management of seminoma. In: Kurth KA (ed) Progress and controversies in the oncological urology. Liss, New York, p 91
Thomas GM (1985) Controversies in the management of testicular seminoma. Cancer 55: 2296
Mirimanoff RO, Shipley U, Dosoretz DE, et al (1985) Pure seminoma of the testis: the results of radiation therapy in patients with elevated human chorionic gonadotropin titers. J Urol 134: 1124
Swartz DA, Johnson DE, Hussey DH (1984) Should an elevated human chorionic gonadotropin titer alter therapy for seminoma? J Urol 131: 63
Herman JG, Sturgeon J, Thomas GM (1983) Mediastinal prophylactic irradiation in seminoma. Proc ASCO 2: 133 (abstract #C-521)
Ball D, Barrett A, Peckham J (1982) The management of metastatic seminoma testis. Cancer 50: 2289
van Oosteram AT, Williams SD, Cortes-Funes H, et al (1984) Treatment of semino-mas with chemotherapy. In: Kurth KA (ed) Progress and controversies in the ontological urology. Liss, New York, p 103
Doornbos JF, Hussey DH, Johnson DE (1975) Radiotherapy for pure seminoma of the testis. Radiology 116: 401
Williams SD, Einhorn L (1985) Treatment of seminoma. In: Marc Garnick (ed) Contemporary issues in clinical oncology. Churchill, Livingstone, p 37
Samuels M (1974) Bleomycin in the therapy of testis tumors. In: Soper WT, Gott AB (eds) New drug seminar on bleomycin. NCI, Bethesda, p 124
Einhorn LH, Donohue J (1977) Cis-diamminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87: 293
Brown JH, Kennedy B) (1965) Mithramycin in the treatment of disseminated testicular neoplasms. N Engl J Med 272: 111
Einhorn LH, Williams SD, Troner M, et al (1981) The role of maintenance therapy in disseminated testicular cancer. N Engl J Med 305: 727
Fitzharris BM, Kaye SB, Saverymuttu S (1980) VP16–213 as a single agent in advanced testicular tumors. Eur J Cancer 16: 1193
Williams SD, Einhorn LH, Greco FA, et al (1980) VP16–213 salvage therapy for refractory germinal neoplasm. Cancer 46: 2154
Aiginger P, Kühböck J, Kuzmits R, et al (1982) VP-16 therapy in cis-platinum resistant testicular tumours. In: Periti P, Grassi GG (eds) Proc 12th Int Congr Chemotherapy Washington, p 1426
Aiginger P, Kühböck J, Kuzmits R, et al (1983) Salvage therapy in testicular tumour patients resistant to vinblastine-bleomycin-cisplatinum. In: Spitzy KH, Karrer K (eds) Proc 13th Int Congr Chemotherapy, Vienna. Egermann, Wien, p 241/20
Williams S, Stablein D, Muggia F, et at (1987) Early stage testis cancer: the testicular cancer intergroup studies. Proc 5th Int Conf Adj Ther Cancer, Tucson, 42 (abstract #30)
Weissbach L. Abschließende Daten der Bonner Therapiestudie, Stadium I. Im Druck.
Hoskin P, Dilly S, Easton D, et al (1986) Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy. J Clin Oncol 4: 1031
Vugrin D, Chen A, Feigl P (1987) Long-term survival rates in the patients with stage I germ cell tumors of the testis (GCTT). Proc 5th Int Conf Adj Ther Cancer, Tucson, 43 (abstract # 31 B)
Carter SK (1979) A perspective on adjuvant chemotherapy of testicular cancer. J Cancer Res Clin Oncol 95: 1
Maier JG, Van Buskirk K (1970) Treatment of testicular germ cell malignancies. JAMA 213: 97
Williams C (1977) Current dilemmas in the management of non-seminomatous germ cell tumors of the testis. Cancer Treat Rev 4: 275
Pizzocaro G, DePalo G, Milani A, et al (1977) Adjuvant chemotherapy related to prognostic subgroups in stage Il testicular carcinoma. Proc ASCO 18 (abstract # C-471)
Hartlapp JH, Weissbach L, Bussar-Maatz R (1987) Adjuvant chemotherapy in nonseminomatous testicular tumour stage II. Int J Androl 10: 277
Vugrin D, Chen A, Feigl P (1987) Long-term survival rates in stage II germ cell tumors of the testis (GCTT). Proc 5th Int Conf Adj Ther Cancer, Tucson, 42 (abstract # 31 A)
Dewar JM, Spagnolo DV, Jamrozik KD, et al (1987) Predicting relapse in stage I nonseminomatous germ cell tumours of the testis. Lancet is 454
Williams SD, Birch R, Einhorn LH, et al (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 316: 1435
Javadpour N (1978) Biologic tumor markers in the management of testicular and bladder cancer. Urology 12: 177
Tesoro-Tess JD, Pizzocaro G, Zanoni F, et al (1985) Lymphangiography and computerized tomography in testicular carcinoma: how accurate in early stage disease? J Urol 133: 967
Einhorn LH, Williams SD, Mandelbaum I, et al (1981) Surgical resection in disseminated testicular cancer following chemotherapeutic reduction. Cancer 48: 904
Aiginger P, Schwarz HP, Kuzmits R, et al (1983) HLA-A, B, C and DR antigens and testicular cancer: a prospective study. Proc AACR 24: 190
Aiginger P (1983) HLA-Antigene und maligne Hodentumoren. In: Aiginger P (Hrsg) Neue Aspekte in der Klinik und Fortschritte in der Chemotherapie der malignen Hodentumoren. Facultas, Wien, S 31
Aiginger P (1983) Chemotherapie bei Patienten mit malignen Hodentumoren; eigene Ergebnisse. In: Aiginger P (Hrsg) Neue Aspekte in der Klinik und Fortschritte in der Chemotherapie der malignen Hodentumoren. Facultas, Wien, S 41
Samuels ML, Lanzotti VJ, Holoye PY, et al (1976) Combination chemotherapy in germinal cell tumours. Cancer Treat Rev 3: 185
Einhorn LH, Williams SD (1980) Chemotherapy of disseminated testicular cancer — a random prospective study. Cancer 46: 1339
Vugrin D, Herr HW, Whitmore WF, et al (1981) VAB-6 combination chemotherapy in disseminated cancer of the testis. Ann Intern Med 95: 59
Peckham MJ, Barrett A, Liew KH, et al (1983) The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin ( BEP ). Br J Cancer 47: 613
Steurer G, Kuzmits R, Pavelka M, et al (1985) Vinblastine induced thrombocytopenia during polychemotherapy of disseminated testicular cancer. Blut 51: 172
Williams S, Einhorn L, Greco A, et al (1985) Disseminated germ cell tumors: a comparison of cisplatin plus bleomycin plus either vinblastine (PVB) or VP-16 (BEP). Proc ASCO 4: 100 (abstract # C-390)
Samson MK, Fischer RL, Stephens RL, et al (1981) Vinblastine, bleomycin and cisdiamminedichloroplatinum in disseminated testicular cancer: response to treatment and prognostic correlations — a SWOG study. Eur J Cancer 16: 1359
Scheulen ME, Niederle N, Höffken K, et al (1985) Ifosfamide/MESNA (IF/ M) alone or in combination with etoposide (IF/M+E): salvage therapy for patients with metastasized nonseminomatous testicular cancer (NSTC). Proc ASCO 4: 97 (abstract # C-379)
Trump DL, Hortvet L (1985) Etoposide and very high dose cisplatin: salvage therapy for patients with advanced germ cell neoplasms. Cancer Treat Rep 69: 259
Wheeler BM, Loehrer PJ, Williams SD, et al (1986) Ifosfamide in refractory male germ cell tumors. J Clin Oncol 4: 28
De Vita)r VT (1983) The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer. Cancer 51: 1209
Goldie JH, Coldman AJ, Gudauskas GA (1982) Rationale for the use of alternating noncross-resistant chemotherapy. Cancer Treat Rep 66: 439
Aiginger P, Schwarz HP, Kuzmits R, et al (1982) Ifosfamide and cisplatinum in testicular tumour patients resistant to vinblastine-bleomycin-cisplatinum. Proc 13th Int Cancer Congr, Seattle, PPS-28: 180 (abstract #1014)
Kuzmits R, Ludwig H, Aiginger P (1988) Ergebnisse mit dem Standard BVP-Therapieprotokoll und mit sequentiell alternierender BVP-EIP Therapie bei Patienten mit ausgedehnt metastasierten Hodentumoren („Bulky disease“). Tumor Diagnostik & Therapie 9: 33
Donohue JP, Einhorn LH, Williams SD (1980) Cytoreductive surgery for metastatic testis cancer: considerations of timing and extent. J Urol 123: 876
Tiffany P, Morse MJ, Bosl G, et al (1986) Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage Ill germ cell tumors. Cancer 57: 978
Kühböck J, Kuzmits R, Ludwig H, et al (1986) Resection of residual tumour after chemotherapy in testicular cancer: observation and late relapse. Blut 53: 132
Kuzmits R, Ludwig H (1986) Late relapse in testicular cancer from a residual tumour. Lancet i: 1207
Vugrin D, Whitmore WF (1984) The VAB-6 regimen in the treatment of metastatic seminoma. Cancer 53: 2422
UICC (1979) TNM-Klassifikation der malignen Tumoren, 3. Aufl. Springer, Berlin Heidelberg New York, S 118
Höffken K, Schmidt CG (1977) Klassifikation und Stadieneinteilung der Hodentumoren. Deutsch Med Wochenschr 102: 249
Aiginger P (1983) Einteilung der Hodentumoren. In: Aiginger P (Hrsg) Neue Aspekte in der Klinik und Fortschritte in der Chemotherapie der malignen Hodentumoren. Facultas, Wien, S 8
Rights and permissions
Copyright information
© 1989 Springer-Verlag/Wien
About this paper
Cite this paper
Aiginger, P., Kuzmits, R. (1989). Hodentumoren. In: Maligne Lymphome, Hodentumoren, Bronchuskarzinom, Ovarialkarzinom. Angewandte Onkologie. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3321-7_2
Download citation
DOI: https://doi.org/10.1007/978-3-7091-3321-7_2
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82106-0
Online ISBN: 978-3-7091-3321-7
eBook Packages: Springer Book Archive